Evotec’s partner Exscientia, a world-leading Artificial Intelligence (AI)-driven drug discovery company, announced today that it has entered a three-year AI drug discovery partnership with leading biopharma company Celgene, including an initial $ 25 million upfront payment and eligibility to receive substantial milestones based on the clinical, regulatory and commercial success of the program. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/celgene-and-evotecs-partner-exscientia-enter-3-year-ai-drug-discovery-collaboration-focused-on-accelerating-drug-discovery-in-oncology-and-autoimmunity-5789
